Renal Denervation Therapy in Hypertensive Patients Undergoing A-Fib Ablation


About this study

We propose a pilot study to assess safety and benefit of renal artery ablation at the time of planned atrial fibrillation ablation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Paroxysmal and Persistent Atrial Fibrillation refractory eligible for AF ablation as per HRS/ECAS/EHRA consensus statement:
    • Paroxysmal AF is defined as two or more episodes of AF lasting less than 7 days in duration during the last 6 months before enrollment
    • Persistent AF is defined as AF lasting more than 7 days or requiring cardioversion for termination
  2. Hypertension (>140/80 mm Hg) on treatment with at least 1 hypertensive medication
  3. GFR >60ml/dl using Cockcroft- Gault equation

Exclusion Criteria:

  1. Secondary causes of hypertension
  2. Severe renal artery stenosis or dual renal arteries
  3. Congestive heart failure with NYHA class III or IV status
  4. EF< 35%
  5. LA Diameter >6 cm
  6. Previous AF ablation
  7. Previous renal artery stent or angioplasty
  8. Severe contrast allergy
  9. Inability to give informed consent
  10. Solitary kidney

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Siva Mulpuru, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer